Antibody named S309 from SARS patient shows promise against COVID-19
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
List view / Grid view
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
In a new article, researchers highlight the need for treatments to combat the potentially lethal overreaction of the immune system in the progression of COVID-19.
Using mass spectrometry, researchers have shown how human cells are changed by infection from SARS-CoV-2, allowing the team to identify drug targets to prevent viral reproduction.
Russian researchers have created a process for the development of mouse models for use in pre-clinical studies of COVID-19 treatments and vaccines.
Researchers have found that molecules from ticks called Evasins have the potential to halt cytokine storms, the leading cause of COVID-19 fatalities.
A new compound named L1 has demonstrated success in mice, by reducing neuroinflammation and decreasing the levels of amyloid plaques, showing potential as an Alzheimer's treatment.
Tested on plaque reducing assays, researchers have identified a lead candidate multivalent carbohydrate-binding module for the treatment of COVID-19.
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
According to a new study, treatments for COVID-19 should focus on cytokines and T-cell counts and their function, rather than patient respiratory function.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Scientists have developed a new antimicrobial peptide therapy named D8 with high efficacy and low toxicity in mice which could be used to fight lung infections.
A group of researchers has used cryo-EM to discover the structure of the remdesivir-bound RNA complex of SARS-CoV-2 and explain how the drug inhibits COVID-19 viral replication.
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
A new AI tool has been created by researchers to identify the best treatment courses and doses for bacterial or viral infections, such as COVID-19.